Compare ICCM & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | BOLT |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 7.1M |
| IPO Year | 2013 | 2021 |
| Metric | ICCM | BOLT |
|---|---|---|
| Price | $2.21 | $3.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 89.0K | 23.6K |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | $139.51 | N/A |
| Revenue Next Year | $75.66 | $133.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.13 | $3.13 |
| 52 Week High | $9.54 | $7.20 |
| Indicator | ICCM | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 33.57 | 51.18 |
| Support Level | $2.15 | $3.14 |
| Resistance Level | $3.59 | $4.33 |
| Average True Range (ATR) | 0.16 | 0.27 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 10.45 | 63.39 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.